SCHEMBL4310317

SCHEMBL4310317

COc1cc(C=Cc2n[nH]c3ccccc23)c([N+](=O)[O-])cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.48
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP3A4 P08684 2/20 0.48
ALOX15 P16050 1/20 0.48
PRKDC P78527 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP19A1 P11511 2/20 0.46
OPRM1 P35372 1/20 0.44
OPRK1 P41145 1/20 0.44
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
LMNA P02545 3/20 0.43
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
PLIN1 O60240 1/20 0.42
PABPC1 P11940 1/20 0.42
PLIN5 Q00G26 1/20 0.42
ABHD5 Q8WTS1 1/20 0.42
HPGD P15428 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4310311 1.00 MAPT (0.48) MAPTALDH1A1KDM4ECYP3A4ALOX15
SCHEMBL4315576 0.84 CHEK1 (0.46) ALDH1A1KDM4EOPRM1OPRK1HPGD
SCHEMBL4315583 0.84 CHEK1 (0.46) ALDH1A1KDM4EOPRM1OPRK1HPGD
SCHEMBL4312109 0.83 CYP2D6 (0.50) MAPTALDH1A1KDM4EOPRM1OPRK1
SCHEMBL4312101 0.83 CYP2D6 (0.50) MAPTALDH1A1KDM4EOPRM1OPRK1
SCHEMBL4318950 0.82 OPRM1 (0.39) MAPTALDH1A1KDM4ECYP3A4ALOX15
SCHEMBL4315408 0.80 NPC1 (0.50) MAPTALDH1A1CYP19A1MEN1KMT2A
SCHEMBL4315404 0.80 NPC1 (0.50) MAPTALDH1A1CYP19A1MEN1KMT2A
SCHEMBL4314385 0.80 KDM4E (0.47) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL4314384 0.80 KDM4E (0.47) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 MAPT 4175/4885ALDH1A1 1250/4885KDM4E 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.